METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE
A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 21. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SEKHAVAT HOUFAR [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-17, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
US2024091178 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003128059 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003128059 | ||
| 003 | DE-627 | ||
| 005 | 20240426155653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003128059 | ||
| 035 | |a (EPA)US2024091178 | ||
| 035 | |a (EPA)77920275 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SEKHAVAT HOUFAR |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHOD OF TREATING A PERSON AFFLICTED WITH A RESPIRATORY CONDITION AND PHARMACEUTICAL FORMULATION INCLUDING DAPSONE |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-21, Last update posted on www.tib.eu: 2024-04-17, Last updated: 2024-04-26 | ||
| 520 | |a A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a A61M: Devices for introducing media into, or onto, the body (introducing media into or onto the bodies of animals a61d0007000000; means for inserting tampons a61f0013260000; devices for administering food or medicines orally a61j; containers for collecting, storing or administering blood or medical fluids a61j0001050000); devices for transducing body media or for taking media from the body (surgery a61b; chemical aspects of surgical articles a61l; magnetotherapy using magnetic elements placed within the body a61n0002100000); devices for producing or ending sleep or stupor | |
| 650 | 4 | |a che | |
| 650 | 4 | |a med | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ASOTRA SATISH |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 21. März |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/77920275/publication/US2024091178A1?q=US2024091178 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 | ||